15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for BLRX yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $2.78 current
Highest Target—
Average Target—
Lowest Target—
BLRX analyst recommendation trends
86420
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Strong BuyBuyHoldSellStrong Sell
RATING
DEC
JAN
FEB
MAR
APR
MAY
Strong Buy
0
0
0
0
0
0
Buy
2
2
2
2
2
1
Hold
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
2
2
2
2
2
1
As of May, 1 of 1 firms rate BLRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BLRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 1 analysts
Next period, 1 analysts expect BioLineRx Ltd to earn $0.00 a share (range $0.00 – $0.00), versus $0.00 a year earlier. Full-year consensus is $0.00, growing to $0.00 the year after.
REVENUE · NEXT QUARTER
$375.0K
Range $375.0K – $375.0K · 1 analysts · -12% YoY
Revenue is expected to reach $375.0K (range $375.0K – $375.0K), -12.2% year-over-year. Full-year consensus is $1.9M, rising to $1.9M next year.
Top analysts covering BioLineRx Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BLRX.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #298
Buy
$26.00+835.3% to target
Overall win rate
33%
+ Follow
#2
JW
Justin Walsh
Jones Trading
Buy
$12.00+331.7% to target
Coverage
—
+ Follow
BLRX stock forecast FAQ
Who is the most accurate analyst covering BLRX?+
Among analysts who currently cover BLRX, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #298). Their current call is Buy with a $26.00 target.
What is BioLineRx Ltd's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 1 analysts. Full-year EPS is projected at $0.00, rising to $0.00 the following year.
How much revenue is BioLineRx Ltd expected to report next quarter?+
Consensus revenue is $375.0K (range $375.0K – $375.0K). Full-year revenue is projected at $1.9M, growing to $1.9M next year.
Have analysts been upgrading or downgrading BLRX lately?+
As of May, 1 of 1 firms rate BLRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BLRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
